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Background: Young adult survivors of childhood acute lymphoblastic leukemia (ALL) treated with protocols
including cranial radiotherapy demonstrate a persistent weight gain and reduced final height. Published reports on
the effects on growth of different oncologic therapies are conflicting and difficult to interpret because they
combined children treated with both cranial irradiation and multi-agent chemotherapy. Our study investigated the
effect of chemotherapy alone on body mass index (BMI) and on growth at the achievement of final height in a
homogeneous cohort of Italian childhood ALL survivors.
Methods: We retrospectively studied 162 Caucasian patients treated on the Italian Association of Pediatric
Hematology and Oncology protocols without radiotherapy between 1989 and 2000 at five Italian centers with 107
inclusions (58 males). Height- and BMI-standard deviation score (SDS) were collected at diagnosis of ALL, at the end
of treatment and at the achievement of final height. Changes in height SDS and BMI SDS with time were analyzed
using dependent sample Student's t-test.
Results: A significant reduction of height-SDS was documented during treatment in both genders. This reduction of
height-SDS was not followed by an appropriate catch-up growth, despite the achievement of a mean final height
within the normal range. At diagnosis females showed a lower mean BMI-SDS than males. During treatment, in the
whole population, BMI-SDS increased significantly. After it, while males lost BMI-SDS, females showed its persistent
increase.
Conclusions: Survivors of childhood ALL generally seemed to achieve a normal final height with a BMI within the
normal range. These parameters appeared to be only minimally affected by chemotherapy. Nevertheless, height
catch-up growth was not completed after chemotherapy in both genders and all patients experienced an
increase of BMI-SDS during chemotherapy that only females seemed to conserve until the achievement of final
height.* Correspondence: iughetti.lorenzo@unimore.it
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Acute lymphoblastic leukemia (ALL) is the most common
malignancy in children and represents 80% of all leukemia
cases [1]. Recent progress in risk-adapted treatment for
childhood ALL has secured eight-year event-free survival
rates of approximately 90% [2-4]. Consequently, the late
side-effects of the cancer treatment have obtained an
increased attention and the long-term monitoring of sur-
vivors has become an important part of their overall
health care [5]. Treatment of ALL during childhood is as-
sociated with final height deficit. Young age at diagnosis
and radiotherapy are considered the major risk factors [6].
Moreover, adult survivors of childhood ALL have a four-
fold excess risk of mortality from cardiovascular disease.
Obesity seems highly prevalent among female and survi-
vors treated with radiotherapy [7].
Nowadays, ALL survivors form the largest group of
long-term survivors from childhood cancer, even if they
are a heterogeneous group considering therapeutic proto-
cols. In last decades, in most of them, cranial radiotherapy
has been replaced by intrathecal chemotherapy, as stand-
ard central nervous system prophylaxis and treatment, and
a reduced percentage of children have received cranial ra-
diation [8] with a consequent reduction of sequelae related
to this treatment modality. However, it has been suggested
that also chemotherapy can negatively affect growth and
endocrine functions [9,10]. Published reports on the effects
on growth of these therapies are conflicting and difficult to
interpret because most studies have analyzed growth in
children treated with both cranial irradiation and combin-
ation chemotherapy and disentangling the adverse contri-
bution of these two major therapeutic modalities has
proved tricky [11-13].
To evaluate the impact on growth, we performed a
retrospective multicenter study in a large pediatric ALL
population treated without radiotherapy, followed until
the achievement of final height.
Methods
Design and setting
This study was a longitudinal, retrospective and multi-
center study: we reviewed the clinical notes of patients
treated for ALL at five Italian pediatric oncologic
centers (Modena, Turin, Rome, Rimini and Parma) on
Italian Association of Pediatric Hematology and On-
cology (AIEOP) protocols, without radiotherapy, from
1989 to 2000, and followed until the achievement of
adult height. Inclusion criteria comprised the success-
ful completion of the treatment (standard risk proto-
cols) and a continued first remission. Exclusion criteria
included: relapse, exposure to radiotherapy and/or
bone marrow transplant, the presence of other diseases
potentially influencing growth (i.e. Down’s syndrome,
neurofibromatosis type 1) and of chronic treatmentwith any other medication apart from the AIEOP protocols
which might affect growth (i.e. growth hormone therapy,
sex steroid) and lack of complete auxological data. Details
concerning ALL treatment protocols were published else-
where [14] and summarized in Table 1.
Provincial Ethical Committee approved the protocol
study (practice 185/11).Data collection
Age, height and weight at diagnosis of ALL (sT), at the end
of treatment (EoT), and at final height (FH) were extracted
from the record of each eligible patient. Uniformly, in every
center, height was measured to the nearest 0.1-cm with a
wall-mounted stadiometer (Harpenden, Crymych; UK);
body weight was measured to the nearest 0.1-kg and body
mass index (BMI) was obtained from the weight in kg/
height in meters squared and expressed as standard
deviation-score (SD-S) with respect to chronological age.
The auxological instruments were routinely checked
and calibrated. Height- and BMI- SDS were calculated
for each value using age- and sex- specific World
Health Organization (WHO) growth chart 2007 [15].
Parental height was also collected to estimate target
height (TH), calculated according to the formula:
[(mother’s height +13) + father’s height]/2 in males and
[(mother’s height - 13) + father’s height]/2 in females
[16]. Final height (FH) was defined as the standing
height achieved when the linear growth velocity during
the preceding year was less than 1 cm/year.
For each participant, demographic and therapeutic
information was obtained, including gender, ethnicity,
diagnostic white cell count (WBC) at sT and treatment
modalities.Data analysis
All results, apart from ages expressed by median, were
reported as the mean ± SD. Parametric statistical analysis
(STATISTICA™ software, StatSoft Inc., Tulsa, OK, USA)
was performed using dependent sample Student’s t-test
to detect mean changes in height SDS and BMI SDS
from diagnosis of ALL to final height.
Data were also analyzed according to gender and to
groups of age (younger or older than four years at
diagnosis). Independent t-test was performed to detect
differences between groups. Gender, WBC, age at diag-
nosis, height at diagnosis and BMI at diagnosis, genetic
target height were analyzed in a univariate regression
model with final height SDS as dependent variable
through Pearson’s correlation. Potential predictors of
final height SDS and BMI SDS at FH were analyzed by
multivariate regression models.
A P value below 0.05 was considered statistically
significant.
Table 1 Characteristics of treatment protocols
Protocols 87 8801 8802 8805 9101 9102 9501 – 9502 armA 9502 armB 2000
PDN 2500 1830 1830 150 2030 1970 1970 1620 1910
VCR 20.5 9 12 9 12 12 12 15 18
DNM 180 160 160 - 120 120 - 120 120
MTX IT ٧ ٧ ٧ ٧ ٧ ٧ ٧ ٧ ٧
L-ASP 5400 80000 80000 - 80000 80000 120000 120000 80000
6-MP 6000 29920 25900 - 5100 28920 27350 6710 6830
MTX IV 180 1540 1500 30 1488 1500 1488 1500 1500
CPM - 2000 3000 1600 1000 3000 1000 3000 2500
DESA - 189 249 300 249 249 261 297 409
6-TG - 900 900 - 840 840 780 780 780
ARA-C - 600 600 900 600 1800 600 1600 600-1800
IFO - - - 12000 - - - - -
VM-26 - - - 600 - - - - -
ADM - 60 120 150 120 120 120 120 60-120
Num. patients exposed 2 1 2 4 5 28 2 57 6
Legend: Drugs are expressed as cumulative dose (mg/mq). PDN, prednisolone; VCR, vincristine; DNM, daunorubicin; MTX, metotrexate; IT, intrathecal; ٧ included;
L-ASP; L-asparaginase (UI/mq); 6-MP, 6-mercatopurine; IV, intravenously; CPM, cyclophosphamide; DESA, dexamethasone; 6-TG, 6-thioguanine; ARA-C, cytosine
arabinoside.; IFO, ifosfamide; VM-26,teniposide; ADM, adriamycin.
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Of 162 Caucasian patients treated on AIEOP ALL87, 88,
91, 95 and 2000 protocols without radiotherapy from 1989
to 2000, 107 met inclusion criteria. Causes of exclusion
enclosed: relapse (7.4% of initial population), exposure to
radiotherapy (6.7%) and lack of data (19.7%). None wasTable 2 Meadian age (years; range); Height-SDS (media ± SDS
± SDS) and BMI-SDS (media ± SDS) in study population and n
Total participant
population
Participants males
(58 pts)
Participant
(49 pts)
Meadian age
sT 5.57 (1.20 – 13.73) 5.93 (1.31 – 12.85) 5.15 (1.20 –
EoT 7.60 (3.0 – 15.98) 7.97 (3.23 – 14.97) 7.16 (3.0 – 1
FH 17.52 (14.05 – 23.98) 17.68 (14.05 – 23.98) 17 · 24 (14.0
Height-SDS
sT 0.61 ± 1.04 0.62 ± 1.05 0.60 ± 1.05
EoT 0.25 ± 1.08 (0.000) 0.30 ± 1.09 (0.003) 0.19 ± 1.09
FH 0.18 ± 1.13 (0.000) 0.27 ± 1.03 (0.013) 0.07 ± 1.25
Height-SDS adjusted TH
sT 0.45 ± 1.22 0.51 ± 1.38 0.38 ± 1.22
EoT 0.04 ± 1.2 (0.000) 0.18 ± 1.36 (0.043) -0.12 ± 1.11
FH 0.15 ± 1.20 (0.000) 0.37 ± 1.23 -0.13 ± 1.11
BMI-SDS
sT 0.15 ± 1.32 0.39 ± 1.30 -0.12 ± 1.31
EoT 0.58 ± 1.34 (0.000) 0.82 ± 1.29 (0.010) 0.29 ± 1.36
FH 0.51 ± 1.03 (0.010) 0.49 ± 1.09 0.54 ± 0.96
Only significant p-values versus sT are expressed into brackets. † Significant p-value
females: p 0.0431).excluded because of the presence of other diseases or of
other chronic treatment potentially influencing growth.
Only auxological parameters at sT were available in the 32
non-participants patients excluded because of lacking data.
No statistical differences were detected between included
and excluded patients among available variables (Table 2).); Height-SDS adjusted according to target height (media
on-participants and according to gender from sT to FH
females Non-participans males
(17 pts)
Non-participans females
(15 pts)
13.73) 5.84 (1.15 – 12.74) 5.12 (1.14 – 13.45)
5.98) / /
5- 23.7) / /
0.60 ± 1.02 0.62 ± 1.09
(0.000) / /
(0.000) / /
/ /
(0.000) / /
(0.022) / /
† 0.35 ± 1.24 -0.09 ± 1.20
(0.015) † / /
(0.001) / /
s Males versus Females (BMI-SDS sT: males vs females: p 0.0427; EoT: males vs
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are shown in Table 2.
Among participants, there was no significant difference
between male and female groups in age. The median time
from diagnosis to assessment of FH was 11.90 ± 3.26 years
(range 4.23 -18.46).
Table 2 lists anthropometric data over time.
At every step-time, both males and females had a
mean height- and BMI-SDS within the normal range
(Figures 1 and 2). At sT, children appeared generally well-
nourished, showing a mean SDS of + 0.61 for height
and +0.15 for BMI. Only one girl presented a height-SDS
less than -2 SD, but appropriate for her TH SDS (corre-
sponding to -2.70 SD). Analyzing BMI SDS distribution at
sT, 7 children were thin (BMI SDS less than -2 SD) and the
same number were obese (BMI SDS more than +2 SD).Changes with time in height-SDS
In the whole population, a significant reduction of
height-SDS was documented during treatment (from sT
to EoT) in both genders (Table 2). This reduction of
height-SDS was not followed by an appropriate catch-up
growth (Figure 1). In fact, after the end of chemother-
apy, height-SDS further decreased both in females and
in males.
TH-SDS was 0.02 ± 1.10 SDS in the whole group, -0.08 ±
0.79 SDS in males and 0.16 ± 1.40 in females. At sT,
height-SDS adjusted according to TH was higher than at
EoT and at FH (Table 2). The discrepancy in height-SDS
from TH-SDS reduced over time (TH SDS – sT SDS vs
TH SDS – FH SDS: -0.59 vs. -0.16; -0.70 vs. -0.35; -0.44
vs. -0.09 in the whole population, males and females;
respectively). Only females achieved a FH SDS signifi-
cantly reduced than data at sT (Table 2).
In the whole population FH-SDS correlated with
height-SDS at sT (Figure 3A) and TH-SDS (Figure 3B).A
H
ei
gh
t-S
D
S
Figure 1 Mean Height-SDS (A) and mean height-SDS adjusted accord
diagnosis of ALL (sT) are colored in red. Data at the end of treatment (EoT)Changes with time in BMI-SDS
As far as BMI-SDS is concerned, at diagnosis females
showed a lower mean BMI-SDS than males (Table 2).
During follow-up, in the whole population, BMI-SDS
increased significantly both during treatment and after it
until the achievement of FH. After the end of chemo-
therapy the variation in BMI SDS significantly differed
between males and females (BMI SDS FH – BMI SDS
EoT: -0.32 ± 1.23 vs. 0.24 ± 1.34 SDS, respectively, p 0 ·
023): males decreased significantly their BMI-SDS (FH
vs. EoT: p 0.047), whereas females demonstrated no
improvement in BMI SDS (FH vs. EoT: p 0.210)
(Figure 2). Therefore, at FH only females showed a
significant increase of BMI-SDS than at sT (Table 2).Age of exposure to chemotherapy
According to age, 47 children were younger than four
years at diagnosis of ALL (median age 3.06; range 1.20 –
3.89 years). Other 60 presented at sT a median age of
7.79 years (range 4.15 – 13.73 years). There was no signifi-
cant difference between groups in sex distribution. During
chemotherapy, a significant reduction of height-SDS was
registered in both groups and it still persisted at FH
(Table 3). BMI-SDS increased significantly from sT to EoT
in both group, but it was still increased in comparison to
the previous at sT only among children exposed to
chemotherapy at a younger age (Table 3).Multiple regression analysis
Multiple regression analysis identified TH and height SDS
at sT as independent predictive factors for FH (coeff. 0.04,
SE 0.02; coeff. 0.46, SE 0.12, respectively). Height SDS
together with BMI SDS at sT was also identified as
independent predictive factors for final BMI SDS (coeff.
0.30, SE 0.11; coeff. 0.41, SE 0.12, respectively).B
T
H
-a
dj
ut
ed
 H
ei
gh
t-S
D
S
 
ing to TH (B) changes with time in both gender. Legend: Data at
are colored in green. Data at final height (FH) are colored in blue.
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Figure 2 Mean BMI-SDS changes with time in both gender. Legend: Data at diagnosis of ALL (sT) are colored in red. Data at the end of
treatment (EoT) are colored in green. Data at final height (FH) are colored in blue.
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According to our knowledge, this is the first study
examining long-term growth outcomes in a wide cohort
of un-irradiated Italian survivors from childhood ALL.Changes with time in height-SDS
Growth impairment has already been reported as a fre-
quent complication of the treatment of ALL [17]. Patients
treated when younger than four years and who received
cranial irradiation seem to be the more affected [18,19].
Nevertheless, a variety of other factors can contribute to
growth impairment, including decreased nutritional
intake, psychosocial dysfunction, chemotherapy and ster-
oid therapy [20]. Data on long-term growth in children
treated with chemotherapy alone are scarce and discord-
ant [9,12,13,18,21-26].A
F
H
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D
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Height SDS at sT
Figure 3 Significant correlations between FH and height SDS at diagn
(r = 0.410, p = 0.000) in the whole population.Our data demonstrate that chemotherapy minimally af-
fected final height, confirming some short-term previous
published findings [18,24,25,27]. In 2013, Vandecruys and
colleagues described the longitudinal growth of 67 adult
survivors of childhood ALL, treated from 1983 to 1989
according to European Organization for Research and
Treatment of Cancer 58831/2 protocols with chemother-
apy as the only treatment modality, and demonstrated a
decrease in FH SDS from the time of diagnosis of -0.53
SDS in the standard-risk ALL group (45 patients) and
of -0.73 SDS in the medium- or high-risk survivors (22
patients) [26]. In our study, survivors showed at FH a
significant mean height loss of – 0.42 SDS (p 0 .000)
compared to height SDS at diagnosis and, analyzing
height-SDS adjusted according to TH, the loss in SDS
from sT to FH still persisted (-0.30; p 0.000). Differ-
ences could be due to the inclusion in our study of aB
TH
F
H
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D
S
osis (A) (r = 0.571, p = 0.018) and between FH and TH (B)
Table 3 Variation of anthropometric data in patients
according to age (younger or older than 4 years)
< 4 years ≥ 4 years
Height SDS
sT 0.54 ± 1.06 0.67 ± 1.03
EoT 0.14 ± 1.13 (0.000) 0.34 ± 1.05 (0.003)
FH 0.08 ± 1.13 (0.001) 0.26 ± 1.14 (0.004)
BMI SDS
sT -0.03 ± 1.20 0.30 ± 1.40
EoT 0.48 ± 1.42 (0.005) 0.65 ± 1.29 (0.023)
FH 0.49 ± 0.97 (0.005) 0.53 ± 1.08
Only significant p-values versus sT are expressed into brackets.
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therapy protocols. The damage induced by chemotherapy
could impede a complete catch-up growth, even if our
survivors reached a FH within the normality. In fact, only
TH and height-SDS at sT directly correlated with FH and
they were both identified as independent predictive factors
for FH in the multiple regression analysis, demonstrating
than genetic potentiality together with growth pattern be-
fore ALL still remain the two main factors influencing FH.
In irradiated population, girls typically experienced
greater growth impairment than boys [11,28]. Also in
our study, analyzing data adjusted according to TH, only
females showed a significant persistent reduction of
height-SDS data, while males seemed to partially catch
up after the end of chemotherapy. Because of the retro-
spective design of our study and the lack of a description
of pubertal data, we could only hypothesized that it is
possibly due to the early occurrence of puberty in female
survivors of childhood ALL but not in males, as already
described in literature [29,30].
How chemotherapy can affect growth is still unclear,
even because hypothalamic-pituitary cells together with
liver and chondrocyte do not have a high multiplicative
capacity and, therefore, they have not usually been con-
sidered vulnerable to the action of chemotherapeutic
agents. A reduction of growth hormone (GH) secretion
induced by chemotherapy could be supposed. Rose and
colleagues documented a hypothalamic-pituitary abnor-
mality after chemotherapy in 83% of 18 hematological
malignancy survivors (17 ALL) who were referred to
their Clinic because of slow growth [31]. GH deficiency
developed in 9 survivors. Even if this report did not rep-
resent a study of prevalence, authors hypothesized that
chemotherapy alone may affect hypothalamic neurons
through the loss of hypothalamic releasing or inhibitory
hormone functions or through an altered processing of
pituitary hormone. Host factors which might be associ-
ated with greater susceptibility to chemotherapy could
be considered contributing factors [31]. On the contrary,
Vandecruys and colleagues evaluated GH status in theirpopulation through glucagon stimulation test at the end
of chemotherapy. In the 28% of cases, they demonstrated
a decrease of GH secretion. This biochemical status did
not correlate with the reduction in height SDS from
diagnosis or end of treatment to FH [26]. Moreover, pa-
tients with an altered peak GH level at the end of
chemotherapy were retested at the onset of puberty and
demonstrated a normalized response to the GH stimula-
tion test [26]. In older studies, a condition of GH-
deficiency requiring GH replacement therapy has re-
ported prevalence of 0.9 and 1.2% of childhood survivors
of ALL treated with chemotherapy alone [32,33]. In our
study, data were collected retrospectively and we did not
investigate GH secretion in our population. Neverthe-
less, the demonstration of limited growth during chemo-
therapy could support the hypothesis that GH secretion
could be directly and acutely altered by chemotherapeu-
tic agents and that, in acute phases, both ALL and its
treatment can caused severe catabolic effects in children,
leading to increasing protein breakdown and reducing
protein synthesis. The growth-promoting and metabolic
actions of GH are mediated by specific GH receptors.
The absence of or reduction in functional proteins might
result in a condition of partial, transient and reversible
GH insensitivity [34]. All our patients were exposed to
high dose, intravenous MTX associated to its intrathecal
administrations and to glucocorticoids in pre-induction,
induction and re-induction phases (Table 1). Mild late
effects on growth could be due to a direct, structural
negative effect of chemotherapy on epiphysis with partial
recovery [35]. Up to now, we can demonstrate a signifi-
cant and not obvious role of chemotherapy in long-term
growth impairment, but we can only hypothesize a
synergic effect of all chemotherapeutic compounds in
altering the multitude and the functionality of cells in
growth plate.
Changes with time in BMI-SDS
Obesity is probably the most worrisome and common late
effect in survivors of childhood ALL [36]. Razzouk in 2007
documented that 33.7% of 101 young adults treated previ-
ously with chemotherapy-alone for ALL were obese [37].
In addition, children treated for childhood cancer may be
at unusually high risk from the consequences of obesity,
particularly cardiovascular and metabolic comorbidities.
Our data help in clarifying changes in BMI SDS over time,
meanwhile and after chemotherapy for ALL. Excess
weight gain usually starts soon after diagnosis, particularly
during the first year of therapy, and it seems to be main-
tained [20,38]. Nevertheless, up to now, long-term BMI
data in an unirradiated population are not yet fully de-
scribed and short-term data are extrapolated from small
populations [39]. The rate of weight gain varies between
studies [10,37,40-42]. In our study, BMI-SDS increased
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crease persisted until the achievement of FH. Increased
energy intake and reduced habitual physical activity are
commonly considered the main responsible factors of
weight gain. During treatment, patients usually undergo
changes in their lifestyle. The loss of physical activity
may start during hospitalization or unwellness period
of the patient, but it persists into adulthood due to a
number of factors, including diminished exercise
capacity, impaired motor function, diminished interest
in recreational activity and over-protectiveness of the
child’s primary caregivers [36]. In adulthood, almost
44% of ALL survivors are unlikely to meet the Centers
for Disease Control and Prevention Recommendations
for physical activity and over 74% are less likely to be
physically active [43] and their dietary intake is not
concordant with specific dietary recommendation [44].
In our study, BMI SDS at sT is identified as independ-
ent predictive factor for BMI-SDS at FH. This might
indirectly document that, independently from the
diagnosis of ALL and its treatment, environmental
factors as a negative lifestyle acquired in the family
setting during first years of life may intervene in the
development of obesity during and after the treatment
of ALL.
Exposure to chemotherapeutic medications seemed to
differ between genders: females seemed more sensitive
to effects of chemotherapy and they might be more at
risk to present greater and more persistent metabolic
alterations than males. Up to now, none of therapeutic
choices and/or doses could explain this sexual dimorph-
ism. Others factors should be considered. Female survi-
vors are already known to be less active and to have a
more unbalanced caloric intake than males [45]. Never-
theless, a definitive explanation of gender dymorphism
could be identified only when other risk factors respon-
sible for an indirect damage of the hypothalamus-
pituitary region or of the metabolic pathways will be
studied [36]. Our findings confirm and reinforce recent
Harper’s data [27,46]. The group from Cambridge pre-
sented data from only 27 ALL survivors (17 females)
who reached FH. Only in females, persisting increases in
weight-SDS and BMI-SDS (+1.45 vs. +0.46, p < 0.0001)
were evident at FH [27].
In our cohort, age at diagnosis did not correlate with
final BMI SDS and it was not identified as its independ-
ent predictive factors. Nevertheless, examining popula-
tion according to age-subgroups (younger and older
than 4 years at sT), only younger children presented a
persistent increase of BMI SDS after the end of chemo-
therapy. This might support that chemotherapy acts
similarly to radiotherapy in altering body composition
later-in-life via blunting hypothalamic leptin sensitivity
and via modification of metabolism.Conclusions
In conclusion, our study demonstrates that chemotherapy
alone, as in AIEOP protocols, minimizes the loss in FH
SDS together with the increase in BMI SDS in adult survi-
vors of childhood. These results could be positively influ-
enced by the fact that, in all the included Italian centers,
the management of oncologic patients involves pediatric
endocrinologists from the early stages of treatment, allow-
ing early evaluation of pathological conditions and, conse-
quently, early interventions. Nevertheless, both males and
females experienced a loss in height-SDS during chemo-
therapy that was not followed by an appropriate catch-up
growth, and an increase of BMI-SDS. Physicians have to
keep in mind that cancer survivors, because of treatment
(potential cardiotoxic chemotherapy), are prone to de-
velop cardiovascular disease. Obesity can increase the risk
for morbidity and mortality due to diabetes, coronary ar-
tery disease, atherosclerosis and other diseases related to
overweight in adulthood [38], especially in females [47].
Our findings confirmed females as more at risk of either
becoming or persisting obese long after chemotherapy.
This enables us to focus our efforts in preventing their
weight gain and long-term complications of obesity.
Nevertheless, the majority of adult survivors are followed
by primary health care physicians, rather than by an onco-
logic center. This leads to an imperative need: educate all
health workers on preventing these risks and on develop-
ing specific intervention strategies, including correct diet-
ary and lifestyle choices [48] in ALL survivors, even if
treated with chemotherapy only.
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